Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Mark Netherton

Interventional Pain Medicine Mt Pleasant, SC Medical Doctor

NPI 1437267473 CMS profile 292606

1625 Hospital Dr, Mt Pleasant, SC 29464

Open in the dashboard

General payments

$101,927

176 records reported · program years 2019–2023

Research payments

$5,545

Paid to them · 1 record reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Mark Netherton of Mt Pleasant, SC is reported in the CMS Open Payments database as having received $101,927 across 176 general payments and $5,545 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $464 13
2022 General $1,984 16
2021 General $18,879 28
2020 General $6,270 13
2019 General $74,331 106
2019 Research $5,545 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Netherton
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Mark Netherton were reported at $0. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Mark Netherton Interventional Pain Medicine median Middle half National median
2019 $74,331 $684 $216–$2,079 $163
2020 $6,270 $382 $122–$1,109 $114
2021 $18,879 $552 $167–$1,554 $132
2022 $1,984 $605 $187–$1,924 $149
2023 $464 $671 $195–$1,915 $160
2024 $0 $684 $206–$1,837 $164
2025 $0 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Boston Scientific Corporation $34,568 60 payments
  2. Abbott Laboratories $29,941 57 payments
  3. Vertiflex, Inc. $28,552 39 payments
  4. Vertos Medical, Inc. $8,757 16 payments
  5. SI-BONE, Inc. $59 1 payment
  6. Curonix LLC $19 1 payment
  7. Flowonix Medical Incorporated $19 1 payment
  8. Relievant Medsystems, Inc. $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Consulting Fee $49,380 33 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $39,150 13 payments
  3. Travel and Lodging $7,669 23 payments
  4. Food and Beverage $5,728 107 payments
Products named General payments · program years 2019–2023
  1. Superion ISS $28,552 39 payments
  2. Proclaim Family of SCS IPGs $25,196 28 payments
  3. SPECTRA WAVEWRITER Pain Management $16,397 15 payments
  4. mild Device Kit $7,826 9 payments
  5. WAVEWRITER ALPHA $5,738 2 payments
  6. SPECTRA WAVEWRITER Pain Management $5,287 10 payments
  7. Swift-Lock SCS $2,960 2 payments
  8. GENERAL PAIN MANAGEMENT $2,494 11 payments
  9. GENERAL - PAIN MANAGEMENT $2,116 6 payments
  10. Neuromodulation Dspsbls and Accs $1,280 1 payment
  11. Other $3,929 54 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2023
  1. Vertiflex, Inc. $5,545 1 payment

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$9,730

Medicare's payments for the services billed

Medicare patients

65

Average age 71

Services billed

119

35 women, 30 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 26%
Ischemic heart disease 26%
Atrial fibrillation 20%
Chronic kidney disease 20%
Depression 20%
Osteoporosis 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

177 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record